Results 11 to 20 of about 250,267 (258)

Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

BMC Cancer, 2022
Background Multiple myeloma remains an incurable disease with multiple relapses due to residual myeloma cells in the bone marrow of patients after therapy.
Alexander Schmitz, Rasmus Froberg Brøndum, Hans Erik Johnsen, Ulf-Henrik Mellqvist, Anders Waage, Peter Gimsing, Davine Hofste op Bruinink, Vincent van der Velden, Bronno van der Holt, Markus Hansson, Niels Frost Andersen, Ulf Christian Frølund, Carsten Helleberg, Fredrik H. Schjesvold, Lucia Ahlberg, Nina Gulbrandsen, Bjorn Andreasson, Birgitta Lauri, Einar Haukas, Julie Støve Bødker, Anne Stidsholt Roug, Martin Bøgsted, Marianne T. Severinsen, Henrik Gregersen, Niels Abildgaard, Pieter Sonneveld, Karen Dybkær   +26 more
doaj   +1 more source

Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909

Haematologica, 2012
Background In the present study, the prognostic impact of minimal residual disease during treatment on time to progression and overall survival was analyzed prospectively in patients with mantle cell lymphoma treated on the Cancer and Leukemia Group B ...
Hongtao Liu, Jeffrey L. Johnson, Greg Koval, Greg Malnassy, Dorie Sher, Lloyd E. Damon, Eric D. Hsi, Donna Marie Bucci, Charles A. Linker, Bruce D. Cheson, Wendy Stock   +10 more
doaj   +1 more source

Which are the most promising targets for minimal residual disease-directed therapy in acute myeloid leukemia prior to allogeneic stem cell transplant?

Haematologica, 2019
Minimal residual disease has emerged as an important prognostic factor for relapse and survival in acute myeloid leukemia. Eradication of minimal residual disease may increase the number of patients with long-term survival; however, to date, strategies ...
Brian Ball, Eytan M. Stein
doaj   +1 more source

Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia

Haematologica, 2017
Our aim was to improve outcome prediction after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia by combining cytogenetic and molecular data at diagnosis with minimal residual disease assessment by multicolor flow-cytometry at
Betül Oran, Jeff L. Jorgensen, David Marin, Sa Wang, Sairah Ahmed, Amin M. Alousi, Borje S. Andersson, Qaiser Bashir, Roland Bassett, Genevieve Lyons, Julianne Chen, Katy Rezvani, Uday Popat, Partow Kebriaei, Keyur Patel, Gabriela Rondon, Elizabeth J. Shpall, Richard E. Champlin   +17 more
doaj   +1 more source

Liquid biopsies and minimal residual disease in lymphoid malignancies

Frontiers in Oncology, 2023
Minimal residual disease (MRD) assessment using peripheral blood instead of bone marrow aspirate/biopsy specimen or the biopsy of the cancerous infiltrated by lymphoid malignancies is an emerging technique with enormous interest of research and ...
Maroun Bou Zerdan, Joseph Kassab, Ludovic Saba, Elio Haroun, Morgan Bou Zerdan, Sabine Allam, Lewis Nasr, Walid Macaron, Mahinbanu Mammadli, Sarah Abou Moussa, Chakra P. Chaulagain   +10 more
doaj   +1 more source

Epigenetic insights into minimal residual disease detection in cancer [PDF]

Genes and Diseases
Lingao Ju, Gang Wang, Zilin Xu, Wan Xiang, Hongwei Peng, Mengxue Yu, Shenjuan Li, Yi Zhang, Kaiyu Qian, Yu Xiao   +9 more
doaj   +2 more sources

Liquid biopsies and minimal residual disease in myeloid malignancies

Frontiers in Oncology, 2023
Minimal residual disease (MRD) assessment through blood component sampling by liquid biopsies (LBs) is increasingly being investigated in myeloid malignancies.
Sabine Allam, Kristina Nasr, Farhan Khalid, Zunairah Shah, Mahammed Ziauddin Khan Suheb, Sana Mulla, Sindhu Vikash, Maroun Bou Zerdan, Faiz Anwer, Chakra P. Chaulagain   +9 more
doaj   +1 more source

Dynamics of Minimal Residual Disease in Neuroblastoma Patients

Frontiers in Oncology, 2019
Neuroblastoma is a common extracranial solid tumor of neural crest (NC) origin that accounts for up to 15% of all pediatric cancer deaths. The disease arises from a transient population of NC cells that undergo an epithelial-mesenchymal transition (EMT ...
Suguru Uemura, Toshiaki Ishida, Khin Kyae Mon Thwin, Nobuyuki Yamamoto, Akihiro Tamura, Kenji Kishimoto, Daiichiro Hasegawa, Yoshiyuki Kosaka, Nanako Nino, Kyaw San Lin, Satoru Takafuji, Takeshi Mori, Kazumoto Iijima, Noriyuki Nishimura   +13 more
doaj   +1 more source

Metabolic memory underlying minimal residual disease in breast cancer

Molecular Systems Biology, 2021
Tumor relapse from treatment‐resistant cells (minimal residual disease, MRD) underlies most breast cancer‐related deaths. Yet, the molecular characteristics defining their malignancy have largely remained elusive.
Ksenija Radic Shechter, Eleni Kafkia, Katharina Zirngibl, Sylwia Gawrzak, Ashna Alladin, Daniel Machado, Christian Lüchtenborg, Daniel C Sévin, Britta Brügger, Kiran R Patil, Martin Jechlinger   +10 more
doaj   +1 more source

The Value of Minimal Residual Disease (and Diamonds) [PDF]

Biology of Blood and Marrow Transplantation, 2017
n ...
openaire   +3 more sources